# SAB Biotherapeutics, Inc.

**SABS**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001833214


# None

### No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $172.8M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, short runway, thin data, dege...<br>not computable: fortress balance sheet |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 9, 2026<br>248 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026 |
| **Last close** | $3.10<br>2026-11-11; market equity $279.3M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 9, 2026*

We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 98.2** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | 53.5% | (6.6%) | | 98.2 | 801 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 28.9** | | | | | | |
| Twelve-month failure probability | 0.11% | 0.08% | | 54.5 | 247 | 2026-09-30 |
| Altman Z double-prime | 6.90 | (0.35) | | 14.5 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 9.46x | 2.95x | | 17.7 | 827 | 2025-12-31 |
| **Growth and financing, sleeve percentile 50.7** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *current value must be positive and the base must exceed $100,000* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | 50.3% | 2.2% | | 7.9 | 695 | 2025-12-31 |
| Net share issuance, one year | 448.5% | 2.5% | | 93.5 | 628 | 2026-03-02 |

## Warnings

*4 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 448.5% |
| Short runway | cash runway is 3.2 months |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-11-11 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (2.5%) | (1.9%) | 50 |
| Distance from 52-week high | (32.2%) | (27.8%) | 46 |
| EBIT to enterprise value | not computable | (1.6%) | |
| Free cash flow yield | (16.3%) | (1.0%) | 27 |
| Book value to price | 0.75 | 0.27 | 80 |
| Sales to price | 0.00 | 0.29 | 0 |
| Composite equity issuance, five years | 410.9% | 20.8% | 97 |
| Relative strength against the sector, log excess return | (0.19) | (0.19) | 50 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $14.4M |
| Operating cash flow, four quarters | -$53.9M |
| Months of runway | 3.2 |
| Days since last periodic filing | 7 (10-Q received Nov 5, 2026) |
| Median daily dollar volume, 63 sessions | $1.5M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | $13.3M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$44.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 3 | assets | us-gaap:Assets | $172.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 4 | assets | us-gaap:Assets | $44.2M | 2024-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 5 | current assets | us-gaap:AssetsCurrent | $101.1M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $10.7M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$110.9M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$49.0M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 9 | book equity | us-gaap:StockholdersEquity | $151.5M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 10 | liabilities | us-gaap:Liabilities | $21.3M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$38.1M | 2023-12-31 | 2025-03-31 | 10-K | 25-046994 |
| 12 | interest expense | us-gaap:InterestExpense | $315,284 | 2023-12-31 | 2024-03-29 | 10-K | 24-038219 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.3M | 2024-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.2M | 2023-12-31 | 2025-03-31 | 10-K | 25-046994 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $23.9M | 2022-12-31 | 2024-03-29 | 10-K | 24-038219 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $933,156 | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$34.3M | 2024-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $337,262 | 2024-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$25.1M | 2023-12-31 | 2025-03-31 | 10-K | 25-046994 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $197,154 | 2023-12-31 | 2025-03-31 | 10-K | 25-046994 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$23.5M | 2022-12-31 | 2024-03-29 | 10-K | 24-038219 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.2M | 2022-12-31 | 2024-03-29 | 10-K | 24-038219 |
| 24 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $3.0M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 25 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $13.3M | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 26 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 27 | current assets | us-gaap:AssetsCurrent | $23.8M | 2024-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 28 | current liabilities | us-gaap:LiabilitiesCurrent | $8.0M | 2024-12-31 | 2026-03-09 | 10-K | 26-000003 |
| 29 | assets | us-gaap:Assets | $83.9M | 2023-12-31 | 2025-03-31 | 10-K | 25-046994 |
| 30 | assets | us-gaap:Assets | $50.9M | 2022-12-31 | 2024-03-29 | 10-K | 24-038219 |
| 31 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 50,951,037 | 2026-03-02 | 2026-03-09 | 10-K | 26-000003 |
| 32 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 9,288,868 | 2025-03-21 | 2025-03-31 | 10-K | 25-046994 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.